The study is designed to test the ability of phenoxodiol to reverse the resistance that develops in most ovarian cancers to standard chemotherapy. The study was conducted at Yale New Haven Hospital, as well as at the Royal Women’s Hospital, Melbourne, Australia.
“What we are seeing with phenoxodiol is an encouragingly high proportion of tumors either shrinking or stabilizing with standard drugs, when we know that the tumor is unlikely to respond to those standard drugs alone,” said Dr Michael Kelly, fellow at Yale University School of Medicine.
The Yale researchers reported that 74% of patients with late-stage, platinum-resistant tumors who received the phenoxodiol and cisplatin combination showed evidence of either tumor shrinkage or no increase in tumor size.
Marshall Edwards licensed rights to bring phenoxodiol to market globally from its majority owner, the Australian biotechnology company Novogen.